WO2015076359A1 - Compose inhibiteur du proteasome - Google Patents

Compose inhibiteur du proteasome Download PDF

Info

Publication number
WO2015076359A1
WO2015076359A1 PCT/JP2014/080859 JP2014080859W WO2015076359A1 WO 2015076359 A1 WO2015076359 A1 WO 2015076359A1 JP 2014080859 W JP2014080859 W JP 2014080859W WO 2015076359 A1 WO2015076359 A1 WO 2015076359A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
proteasome
pharmaceutically acceptable
atom
Prior art date
Application number
PCT/JP2014/080859
Other languages
English (en)
Japanese (ja)
Inventor
章良 浅井
雄加 海野
周東　智
周平 川村
Original Assignee
国立大学法人北海道大学
一般社団法人ファルマバレープロジェクト支援機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人北海道大学, 一般社団法人ファルマバレープロジェクト支援機構 filed Critical 国立大学法人北海道大学
Priority to JP2015549201A priority Critical patent/JP6468562B2/ja
Publication of WO2015076359A1 publication Critical patent/WO2015076359A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel compound having proteasome inhibitory activity, a proteasome inhibitor containing the compound, a pharmaceutical composition containing the compound as an active ingredient, particularly a pharmaceutical composition for treating a proteasome-related disease such as cancer.
  • ubiquitin-proteasome system Proteolysis called ubiquitin-proteasome system is used to break down proteins that are no longer necessary for eukaryotic cells, such as they cannot be folded normally, become inactivated by external stress such as active oxygen, or reach the end of their lives. It is known that a system exists.
  • the ubiquitin-proteasome system is a marker that is formed by modifying a protein that is no longer needed with a protein consisting of 76 amino acids called ubiquitin, and the protein is recognized and decomposed by a huge enzyme complex called a proteasome. .
  • the ubiquitin-proteasome system not only processes the degradation of unwanted proteins, but also quantitatively regulates cell cycle-related factors, signal transduction factors, transcription factors, etc. It has been clarified that it is also involved in the control of apoptosis, and it has been found that it is a system related to the basis of life activity. And as abnormalities occur in this ubiquitin-proteasome system, it is known that various modulations are caused to cells, and by controlling the function of this ubiquitin-proteasome system, it is thought that abnormalities in ubiquitin-proteasome are involved. The possibility of treating various diseases and malignant cells in which apoptosis is difficult to induce is pointed out, and proteasome inhibitors are attracting attention as therapeutic agents for various diseases.
  • Proteasome is a huge enzyme complex that recognizes and degrades all proteins labeled with ubiquitin.
  • This complex is called a 19S complex or 11S complex at both ends of a cylindrical structure called a core particle (CP, 20S proteasome) in which four ring structures composed of two ⁇ rings and two ⁇ rings are stacked. It has a shape in which the structure is bound, and proteolysis is performed in the cavity portion in the 20S proteasome.
  • molecules constituting the core particle molecules called ⁇ 1, ⁇ 2, and ⁇ 5 are known to have different catalytic activities such as caspase-like, trypsin-like, and chymotrypsin-like, respectively.
  • proteasome inhibitors for example, compounds such as bortezomib or ester compounds thereof (for example, Patent Documents 1 to 5), compounds having a peptide-like structure such as belactocin, and the like are known.
  • Bortezomib (trade name: Velcade), whose compound name is N-2-pyrazinecarbonyl-L-phenylalanine-L-leucineboronic acid, was first approved in Japan as a treatment for refractory multiple myeloma Proteasome inhibitor. Although the mechanism of action on cancer cells has not been completely elucidated, it has been found that cancer cells stop abnormal cell division and induce apoptosis by accumulation of unwanted proteins in the cells.
  • proteasome inhibitors as pharmaceutical preparations.
  • they have strong side effects.
  • peripheral neuropathy e.g., peripheral neuropathy, gastrointestinal disorders such as vomiting and diarrhea, and myelosuppression are recognized as side effects. This is considered to occur because the proteasome is present in both normal cells and abnormal cells in common, thereby inhibiting the proteasome in normal cells. Therefore, development of a proteasome inhibitor that selectively exerts an effect only in abnormal cells is desired.
  • proteasome inhibitors are expected to be effective therapeutic agents not only in currently approved multiple myeloma but also in other solid tumors.
  • side effects are a problem when proteasome inhibitors are used in the treatment of diseases. Therefore, development of a novel proteasome inhibitor having an inhibitory action and protease selectivity different from those of conventional proteasome inhibitors is required.
  • the object of the present invention is to solve the problems of the prior art, is highly proteasome-selective, and is more irreversible, so there are few side effects even at high doses, which is equivalent to or equivalent to conventional proteasome inhibitory compounds.
  • Non-Patent Document 1 a novel proteasome-inhibiting compound, which improves the currently known proteasome-inhibiting compound, belactocin, and has a proteasome-inhibiting activity higher than that of belactocin.
  • Non-Patent Document 1 a novel proteasome-inhibiting compound, which improves the currently known proteasome-inhibiting compound, belactocin, and has a proteasome-inhibiting activity higher than that of belactocin.
  • such a compound has a large number of asymmetry points in its skeleton, and further improvement is necessary in terms of practicality as a pharmaceutical from the viewpoint of complexity of synthesis, membrane permeability, biological stability, and the like. I faced a new challenge.
  • a 1 and A 2 are each independently a 5-membered or 6-membered aromatic ring, and one or more hydrogen atoms present in the aromatic ring are optionally halogen, hydroxyl group, nitro group, amino group , May be substituted with a group selected from a cyano group or a C1-10 alkyl group, S 1 and S 2 are each independently C1-5 alkylene, and among the carbon atoms present in the alkylene, any one of carbon atoms not adjacent to X and A 1 or A 2 is arbitrary.
  • R 1 is a C1-5 alkyl group
  • R 2 is a C1-10 hydrocarbon group
  • one or two or more carbon atoms present in R 1 and R 2 are replaced with oxygen atoms, nitrogen atoms or sulfur atoms, provided that when two or more atoms are replaced, these atoms are Not adjacent to each other
  • One or more hydrogen atoms present in R 1 and R 2 may be optionally substituted with a substituent selected from halogen, hydroxyl group, carboxyl group, nitro group, amino group or cyano group
  • Y 1 and Y 2 are each independently a hydrogen atom or a boronyl protecting group
  • Y 1 and Y 2 may be combined to form a ring structure
  • m and n are independently of each other, 1, 2 or 3.
  • One or two or more hydrogen atoms of the alkylene group may be optionally substituted with a group selected from halogen, hydroxyl group, nitro group, amino group or cyano group, and Two hydrogen atoms of one carbon atom may be substituted with one oxygen atom to form a carbonyl group, Or formula III
  • ring Y ′ is a C4-10 cycloalkenyl group or arylene group, and one or more ring carbon atoms constituting Y ′ are optionally replaced with an oxygen atom, a nitrogen atom or a sulfur atom.
  • One or two or more hydrogen atoms of each ring member atom may optionally be a group selected from a halogen, a C1-4 alkyl group, a hydroxyl group, a carboxyl group, a nitro group, an amino group, or a cyano group. May be substituted, or two hydrogen atoms of one carbon atom may be substituted with one oxygen atom to form a carbonyl group. Or a pharmaceutically acceptable salt thereof.
  • a proteasome inhibitor comprising an effective amount of the compound of [1] to [8] or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for treating a proteasome-related disease comprising at least one compound of [1] to [8] or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition according to [10], wherein the proteasome-related disease is a tumor.
  • the novel compound which has the proteasome inhibitory activity which is comparable to the conventional compound which has proteasome inhibitory activity, and exhibits suitable protease selectivity and the stability (biostability) in a biological environment is provided. Therefore, the compound of the present invention can be used as an excellent antitumor agent compared with an antitumor agent containing a conventional proteasome inhibitor compound, such as sufficient antitumor activity and few side effects.
  • FIG. 1 is a graph showing the results of a reversibility test of the compound of the present invention (bottom) and bortezomib (top), which is a known proteasome inhibitory compound. It can be seen that when bortezomib is washed, the inhibitory activity is greatly reduced, whereas the inhibitory activity of the compound of the present invention is hardly reduced.
  • FIG. 2 is a graph comparing the results of a reversibility test of Compound 4a of the present invention, Compound 11a having a structure similar to the compound of the present invention, and bortezomib, which is a known proteasome inhibitory compound.
  • the vertical axis of the graph shows the ratio when the control chymotrypsin-like proteasome activity is taken as 100%. It can be seen that the similar compound 11a and bortezomib greatly recovers chymotrypsin-like proteasome activity when washed, whereas compound 4a of the present invention keeps chymotrypsin-like proteasome activity low.
  • the present invention relates to a novel compound having proteasome inhibitory activity.
  • the compound of this aspect has the following general formula: It is a compound which has a structure represented by these.
  • proteasome inhibitory compound means a compound having an activity of inhibiting the enzymatic reaction of the proteasome.
  • the proteasome is an enzyme complex, and is considered to have a plurality of enzyme activities such as chymotrypsin-like activity, trypsin-like activity, and caspase-like activity. If any one of them can be inhibited, the “proteasome of the present invention is used. It corresponds to “inhibitory compound”. Of course, it may be possible to simultaneously inhibit a plurality of enzyme activities.
  • the proteasome-inhibiting compound of the present invention is a compound suitable as a pharmaceutical composition as described herein. Thus, when referring simply to a “compound” or “proteasome inhibiting compound”, it is intended to include “pharmaceutically acceptable salts thereof” unless otherwise indicated.
  • alkyl or “alkyl group” includes saturated linear or branched alkyl groups, and unsaturated linear or branched alkyl groups such as alkenyl and alkynyl groups.
  • alkylene or “alkylene group” means a group in which one hydrogen atom is eliminated from the alkyl.
  • cycloalkyl or “cycloalkyl group” includes cyclic saturated alkyl groups and unsaturated cyclic alkyl groups such as alkenyl and alkynyl groups.
  • Groups are also encompassed by “cycloalkyl”. Therefore, the number of carbon atoms in the cycloalkyl in which the number of carbon atoms is specified means the number of carbon atoms in the whole group including the number of carbon atoms contained in these substituted alkyl groups.
  • aryl or “aryl group” means an aromatic hydrocarbon group, such as a group in which a ring member atom is further substituted with an alkyl group or a cycloalkyl group, such as 2-methylphenyl, A group in which a hydrogen atom of an alkyl group or a cycloalkyl group is substituted with an aryl group is also included in the “aryl group”. Therefore, the number of carbon atoms in the aryl group in which the number of carbon atoms is specified means the number of carbon atoms in the whole group including the number of carbon atoms contained in these substituted alkyl groups.
  • the term “hydrocarbon group” is a term encompassing all the “alkyl group”, “cycloalkyl group” and “aryl group”.
  • protecting group is a group for inactivating the reaction activity of a functional group to be protected, and can be easily eliminated by an appropriate reaction to yield the original functional group.
  • boronyl group protecting group includes an ether protecting group, an acetal protecting group, an acyl protecting group, etc., which are protecting groups for the hydroxy group of the boronyl group.
  • Examples of the protecting group for the boronyl group include Although not limited thereto, a pinanediol group, a pinacol group, a methyl group, a phenyl group and the like can be mentioned.
  • S 1 and S 2 may be the same or different independently from each other, and mean alkylene having 1 to 5 carbon atoms. Both S 1 and S 2 may be saturated alkylene or unsaturated alkylene, but are preferably saturated alkylene.
  • the number of carbon atoms may be any as long as it is 1 to 5 (C1 to 5), preferably 2 or 3, and most preferably 3.
  • any one of carbon atoms at both ends that is, a carbon atom adjacent to A 1 or A 2 and a carbon atom other than a carbon atom adjacent to X is ,
  • Optionally may be replaced by S or O, preferably O.
  • S 1 and S 2 are most preferably —CH 2 —O—CH 2 —.
  • a 1 and A 2 are each independently a 5-membered or 6-membered aromatic ring, and one or more hydrogen atoms present in the aromatic ring are optionally halogen, hydroxyl group, It may be substituted with a group selected from a nitro group, an amino group, a cyano group, and a C1-10 alkyl group.
  • Such an aromatic ring is preferably phenyl, pyridyl, furanyl, thiophenyl, naphthyl, biphenyl and the like, and most preferably phenyl.
  • X represents C or N, preferably C.
  • the number of asymmetric points in the skeleton of the compound is small. Accordingly, it is preferable that X is not an asymmetric center, that is, -S 1 -A 1 and -S 2 -A 2 are the same.
  • X is not an asymmetric center, that is, -S 1 -A 1 and -S 2 -A 2 are the same.
  • m and n may be any integer as long as they do not adversely affect the proteasome inhibitory activity of the whole compound, but if too large, the compound itself becomes too large to bind to the proteasome, and is small. Number is preferred. Thus, in a preferred embodiment, m and n are 1, 2 or 3. m and n are independent of each other, and may be the same number or different numbers.
  • R 1 and R 2 independently of each other may be any hydrocarbon group of C1 to 12, and one or more carbon atoms present in the hydrocarbon group are oxygen atoms May be replaced by a nitrogen atom or a sulfur atom, but when two or more atoms are replaced, these atoms are not adjacent to each other.
  • one or more hydrogen atoms of the hydrocarbon group may be optionally substituted with a substituent such as halogen, hydroxyl group, carboxyl group, nitro group, amino group, cyano group.
  • R 1 may be any hydrocarbon group as long as it does not adversely affect the proteasome inhibitory activity of the whole compound, but is preferably a C1-6 hydrocarbon group, more preferably a C1-5 alkyl group. is there.
  • R 1 include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, isopentyl, t-butyl, vinyl, 2-propen-2-yl, and the like.
  • R 2 may be any hydrocarbon group as long as it does not adversely affect the proteasome inhibitory activity of the whole compound, and is a C1-7 hydrocarbon group in a preferred embodiment, and C1-5 in a more preferred embodiment. It is an alkyl group. In another preferred embodiment, R 2 is a natural amino acid side chain.
  • In represents a proteasome inhibitory active site.
  • a known proteasome-inhibiting compound, belactocin A has a portion that binds to a portion called S1 pocket present in the proteasome CP, and in contrast to threonine 1 (Thr1) that is a proteasome active site, It is believed that the ⁇ -lactone ring opens and binds by acylating the threonine residue, thereby inhibiting the enzyme activity.
  • the structure in the above general formula I Is presumed to exhibit proteasome inhibitory activity by binding to the S1 pocket present in the CP of the proteasome and binding of In to Thr1, which is the proteasome active site.
  • In preferably has a site that easily forms a bond such as a hydrogen bond or an electrophilic attack on the hydroxyl group present in the side chain of threonine.
  • proteasome inhibitory active sites present in compounds known as proteasome inhibitory compounds are also preferred as In of the present invention.
  • Examples of In include, but are not limited to, a ⁇ -lactone ring, a boronic acid, a boronic acid ester, an epoxide, and the like, and more preferably a structure having high in vivo stability such as a boronic acid and a boronic acid ester. It is.
  • In is a boronic acid or boronic ester.
  • the proteasome inhibitory compound of the present invention has the following formula I It is a compound represented by these.
  • a 1 , A 2 , S 1 , S 2 , X, R 1 , R 2 , m and n are as defined above.
  • Y 1 and Y 2 are each independently a hydrogen atom or a protecting group for a boronyl group. Y 1 and Y 2 may be combined to form a ring structure. Examples of Y 1 and Y 2 include, but are not limited to, the above-described protecting groups for the boronyl group.
  • Y is a C1-10 alkylene group, and among the carbon atoms present in the alkylene, any one of the carbon atoms not adjacent to O is optionally an oxygen atom, a nitrogen atom or a sulfur atom.
  • one or more hydrogen atoms of the alkylene group may be optionally substituted with a group selected from a halogen, a hydroxyl group, a nitro group, an amino group, or a cyano group.
  • two hydrogen atoms of one carbon atom may be substituted with one oxygen atom to form a carbonyl group.
  • ring Y ′ is a C4-10 cycloalkenyl group or arylene group, and one or more ring carbon atoms constituting Y ′ are optionally an oxygen atom, a nitrogen atom or a sulfur atom.
  • —B (OY 1 ) OY 2 is It is. These structures are also known as inhibitory active sites of known proteasome inhibitory compounds.
  • the compounds of the present invention have the formula IV Where m and n are as defined above. It is a compound represented by these.
  • Any known synthesis method can be used alone or in combination for the synthesis of the compound of the present invention. It will be understood by those skilled in the art that an optimum synthesis method for the compound of the present invention can be appropriately selected and necessary conditions can be appropriately determined. In the following examples, some examples of the synthesis of specific compounds included in the present invention are shown, but it is understood by those skilled in the art that alternative synthetic methods may be used. It is.
  • proteasome inhibitor containing the compound of the present invention is a compound having proteasome inhibitory activity as described above. Accordingly, proteasome inhibitors comprising an effective amount of a compound of the invention are also included in the invention.
  • the “effective amount” means the amount of an active ingredient necessary for achieving the use of the composition, that is, for the composition to function effectively, and there is an adverse effect exceeding the benefit of the use of the active ingredient. An amount that does not occur is preferred. The amount varies depending on the use of the composition, the method of use, the type of compound used as an active ingredient, and the conditions of the intended use. For example, in vitro tests using cultured cells, model animals such as mice and rats, etc. It can be appropriately determined by a test method well known to those skilled in the art, such as a test in the above.
  • the proteasome inhibitor of the present invention contains at least one compound of the present invention as an active ingredient, but further contains other compounds of the present invention and / or known proteasome inhibitory compounds as long as the proteasome inhibitory activity is not adversely affected. It's okay.
  • a component for effectively achieving the proteasome inhibitory activity effect of the compound of the present invention such as a pharmaceutically acceptable carrier and other optional components such as excipients may be included. These other components are well known in the art, and those skilled in the art can appropriately select these components according to the purpose and method of use.
  • composition containing the compound of the present invention is a novel compound, has the property of inhibiting the activity of the proteasome, and also has in vivo stability. It is suitable as. Accordingly, pharmaceutical compositions comprising an effective amount of a compound of the present invention are also encompassed by the present invention.
  • the pharmaceutical composition of the present invention can be suitably used particularly for treating a proteasome-related disease, that is, a disease whose pathological condition is improved by inhibiting the function of the proteasome.
  • proteasome-related disease means a disease in which the activity of the proteasome is related to the onset or exacerbation of the disease.
  • the ubiquitin-proteasome system is considered to perform protein quality control in vivo, and homeostasis cannot be maintained due to an abnormality in this system, which leads to cell abnormalities.
  • proteasome-related diseases include, but are not limited to, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, polyglutamine disease, prion disease, amyotrophic lateral sclerosis, tumors such as cancer, rheumatism And other immune system diseases.
  • Proteasome-inhibiting compounds fail by inhibiting abnormal degradation of normal proteins in cells that cannot maintain homeostasis as a result of excessive degradation of normal proteins due to abnormal ubiquitination of normal proteins and increased proteasome expression Can be eliminated and lead to apoptosis. Therefore, the pharmaceutical composition of the present invention can be suitably used particularly for the treatment of proteasome-related diseases.
  • Proteasome-inhibiting compounds are known to have therapeutic effects, particularly in cancer, and are approved as pharmaceuticals. For example, in tumor cells, it is known that various normal proteins such as p53 are abnormally ubiquitinated, and excessive degradation of these normal proteins plays a part in the cause of tumorigenesis. Conceivable. Proteasome-inhibiting compounds can lead tumor cells to apoptosis by inhibiting abnormal degradation of normal cells. Accordingly, in a preferred embodiment, the pharmaceutical composition of the present invention is used to treat cancer.
  • tumor includes benign tumors and malignant tumors (cancer, malignant neoplasm).
  • cancer includes hematopoietic tumors, including blood cancers, epithelial malignant tumors (cancer, carcinoma) and non-epithelial malignant tumors (sarcoma, sarcoma).
  • Examples of cancer treated with the pharmaceutical composition of the present invention include, but are not limited to, blood cancer, colon cancer, skin cancer and the like.
  • the pharmaceutical composition of the present invention contains at least one compound of the present invention as an active ingredient.
  • other pharmaceutical compounds of the present invention and // Known proteasome inhibitory compounds may be included.
  • it may contain other optional components such as a component for effectively achieving the proteasome inhibitory activity effect of the compound of the present invention, such as a pharmaceutically acceptable carrier and a surfactant, and an excipient. .
  • a component for effectively achieving the proteasome inhibitory activity effect of the compound of the present invention such as a pharmaceutically acceptable carrier and a surfactant, and an excipient.
  • these other components are well known in the art, and those skilled in the art can appropriately select these components according to the purpose and method of use.
  • the dosage form of the pharmaceutical composition containing the proteasome-inhibiting compound of the present invention as an active ingredient is not particularly limited, but tablets, solutions, oil emulsions (emulsion formulations), polymer nanoparticles, liposome formulations, Particulate preparations bound to beads having a diameter of several ⁇ m, preparations attached with lipids, microsphere preparations, microcapsule preparations and the like can be mentioned, and those skilled in the art can appropriately select a suitable dosage form.
  • Examples of the administration method of the pharmaceutical composition of the present invention include any known administration method such as intradermal administration, subcutaneous administration, intramuscular administration, and intravenous administration.
  • the dosage of the proteasome-inhibiting compound of the present invention in the preparation can be appropriately adjusted according to the disease to be treated, the age, body weight, etc. of the patient, but is usually 1 mg to 1000 mg, preferably 10 mg to 100 mg per day. Preferably, it is administered once.
  • the present invention is also a method for preventing and / or treating cancer in a subject, comprising an effective amount of one or more proteasome-inhibiting compounds of the present invention. In a method comprising administering to a subject in need thereof.
  • the “subject” in the present invention may be any individual organism as long as it can suffer from cancer, but preferably human and non-human mammals (eg, mouse, rat, guinea pig, hamster, etc.) Dentates, primates such as chimpanzees, cloven-hoofed animals such as cows, goats, and sheep, terridae such as horses, rabbits, dogs, and cats), and more preferably human individuals.
  • the subject may be healthy or afflicted with some disease, but when cancer prevention and / or treatment is intended, the subject is typically afflicted with cancer.
  • the cancer is a cancer in which abnormally increased proteasome expression is observed.
  • proteasome inhibitory compound of the present invention used in the prevention / treatment method of the present invention examples include any of those described herein.
  • the specific dose of the active ingredient depends on various conditions relating to the subject in need thereof, such as severity of symptoms, general health status of the subject, age, weight, subject sex, diet, timing and frequency of administration, It can be determined in consideration of the drug used in combination, the response to treatment, the dosage form, compliance with the treatment, and the like.
  • a specific dose for example, in the case of the proteasome inhibitory compound of the present invention, it is usually preferable to administer 1 mg to 1000 mg, preferably 10 mg to 100 mg once a day.
  • any known appropriate administration method such as intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration and the like can be used.
  • the prevention / treatment method of the present invention may further include a step of selecting a subject for which administration of the proteasome-inhibiting compound is effective as the subject of prevention / treatment before the administration step.
  • This aspect of the present invention may further include the step of determining the presence or absence of abnormally enhanced proteasome expression in the subject tumor cells prior to the selecting step. Presence / absence of abnormally increased proteasome expression in the subject can be determined by any known technique.
  • the target compounds 6a to 11a were also synthesized by a similar method.
  • the Bn group of compound 13a was removed and then condensed with 16 to give compound 18a.
  • the Boc group of 18a was removed and then condensed with the corresponding carboxylic acid or acyl chloride to obtain the target compounds 6a to 9a.
  • the Bn group of compound 14a was removed, and then condensed with CH 3 NH 2 or 4- (benzyloxy) butan-1-amine to obtain the target compound 10a or 11a, respectively. Details of each synthesis reaction are shown below.
  • the flask was purged with hydrogen and the reaction mixture was stirred under a hydrogen atmosphere for 3 hours.
  • the reaction mixture was filtered through a celite pad and the filtrate was concentrated in vacuo to give the corresponding carboxylic acid as a white amorphous solid.
  • reaction mixture is concentrated in vacuo, the residue is dissolved in AcOEt, washed with 1M HCl, saturated NaHCO 3 and brine, dried over Na 2 SO 4 , and the solvent is removed under reduced pressure to provide compound 18a ( 2.07 g, 4.04 mmol, 68% yield over 3 steps) was obtained as a colorless viscous oil.
  • the flask was purged with hydrogen and the reaction mixture was stirred under a hydrogen atmosphere for 2 hours.
  • the reaction mixture was filtered through a celite pad and the filtrate was concentrated in vacuo to give the corresponding carboxylic acid 19a as a white amorphous solid.
  • Example 2 Proteasome Inhibition Assay The inhibitory activity of various compounds synthesized in Example 1 and other proteasome inhibitory compounds on the human 20S proteasome is shown in Asai et al., Biochem Pharmacol. 2004 Jan 15; 67 (2): 227-34. The procedure was as described. Briefly, 3 nM human 20S proteasome was prepared by reacting various compounds and DMSO in reaction buffer (50 mM Tris-HCl (pH 7.5), 25 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 0.018% SDS).
  • reaction buffer 50 mM Tris-HCl (pH 7.5), 25 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 0.018% SDS.
  • Suc-LLVY-AMC which is a chymotrypsin-like activity-selective substrate
  • 75 ⁇ M Suc-LLVY-AMC which is a chymotrypsin-like activity-selective substrate
  • the fluorescence intensity of the degradation product AMC was measured with a microplate reader.
  • the activity value when treated with DMSO alone was taken as 100%, and the inhibitory activity of various compounds was determined.
  • results are shown in Table 2 and Table 3. As can be seen from the table below, all of the compounds showed a sufficient inhibitory effect on the chymotrypsin-like activity of proteasome CP. Among them, compounds 3a-9a, 11a and 3b-5b are bortezomib which are known proteasome inhibitory compounds. Inhibiting activity equivalent to
  • Example 3 Cell growth inhibition assay (1) Colon cancer cell line HCT 116
  • HCT 116 strain which is a human colon cancer cell line.
  • the experiment was performed according to the product protocol using Cell counting kit-8 (Dojindo Laboratories). Cells were seeded in a 96-well microtiter plate at 3000 cells / well and treated with the test compound for 72 hours. The results are shown in Table 4. As can be seen from Table 4, any compound other than Compound 10a was able to effectively inhibit the growth of HCT 116.
  • MM Multiple myeloma cell line MM.
  • MM which is a multiple myeloma cell line instead of the colon cancer cell line HCT116.
  • 1S and MM Using 1R, the growth inhibitory effect on the cells of the compound of the present invention was verified by the same method as in (1) above.
  • MM The 1S cell line is dexamethasone-sensitive human multiple myeloma cells, MM.
  • 1R is dexamethasone-resistant human multiple myeloma cells, all of which were obtained from ATCC.
  • the compound of the present invention was able to suppress cell proliferation to an extent comparable to that of existing proteasome inhibitors. Moreover, like existing proteasome inhibitors, cell proliferation could be suppressed regardless of the presence or absence of resistance to dexamethasone.
  • Example 4 Inhibitory Activity Reversibility Assay
  • a reversibility assay was performed using compounds 4a, 11a and bortezomib. 15 nM 20S proteasome was preincubated with each inhibitory compound at 25 ° C. for 12 hours. 37.5 ⁇ M Suc-LLVY-amc was then added as a substrate to initiate the “standard assay” reaction of the 20S proteasome. After incubation at 25 ° C. for 1 hour, fluorescence (excitation light: 390 nm, emission light: 450 nm) of each reaction was measured with a VersaMax Pro microplate reader (Molecular Devices).
  • each pre-incubated reaction mixture was subjected to a Microcon Centrifugal Filter (100 kDa molecular weight cut) prior to reaction with substrate to remove inhibitors not bound to the 20S proteasome. Off) and washed 5 times with assay buffer by centrifuging at 11,000 ⁇ g for 3 min. Thereafter, the reaction was carried out by adding a substrate in the same manner as in the “standard assay”.
  • Example 5 Protease selectivity assay To verify the proteasome specificity of the inhibitory activity of the compounds of the present invention, a protease selectivity assay was performed using compound 4a and bortezomib. It was performed as described in Arastu-Kapur et al., Clin. Cancer Res .. 2011, 17 (9), 2734-2743.
  • cathepsin A the activity of 22 ng / mL cathepsin A (R & D systems) and 40 ⁇ M Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys (Dnp)- After incubation with OH (R & D systems) mixed with assay buffer (50 mM MOPS, pH 5.5) at 25 ° C. for 2 hours, fluorescence (excitation light: 320 nm, emission light: 405 nm) of each reaction was obtained. Measured.
  • cathepsin B the activity of cathepsin B (R & D systems) at 40 ng / mL and 10 ⁇ M Z-Leu-Arg-AMC (R & D systems) as a substrate mixed in assay buffer (25 mM MES, pH 5.0) Then, each reaction product was measured for fluorescence (excitation light: 380 nm, emission light: 460 nm).
  • cathepsin G the activity of 8.0 ⁇ U / mL cathepsin G (R & D systems) and 200 ⁇ M Suc-Ala-Ala-Pro-Phe-AMC (Bachem) as an assay buffer (50 mM Tris-HCl, pH 7) were used.
  • the present invention provides a novel proteasome inhibitory compound.
  • a novel proteasome inhibitory compound has irreversible inhibitory activity, high proteasome inhibitory selectivity, and high in vivo stability while having inhibitory activity equivalent to previously known proteasome inhibitory compounds. It can be said that it has many advantages compared to conventional proteasome inhibitory compounds in its use as an active ingredient. Therefore, it is particularly useful as a therapeutic agent for proteasome-related diseases such as cancer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention vise à fournir un nouveau composé possédant une activité inhibitrice du protéasome, une composition pharmaceutique contenant ledit composé, en particulier une composition pharmaceutique pour le traitement du cancer et d'autres maladies liées au protéasome, un procédé pour le traitement de maladies liées au protéasome mettant en œuvre ledit composé, et analogues. Cet objectif est atteint par la fourniture d'un composé représenté par la formule générale (I).
PCT/JP2014/080859 2013-11-21 2014-11-21 Compose inhibiteur du proteasome WO2015076359A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015549201A JP6468562B2 (ja) 2013-11-21 2014-11-21 プロテアソーム阻害性化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013241039 2013-11-21
JP2013-241039 2013-11-21

Publications (1)

Publication Number Publication Date
WO2015076359A1 true WO2015076359A1 (fr) 2015-05-28

Family

ID=53179618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/080859 WO2015076359A1 (fr) 2013-11-21 2014-11-21 Compose inhibiteur du proteasome

Country Status (2)

Country Link
JP (1) JP6468562B2 (fr)
WO (1) WO2015076359A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536635A (ja) * 2015-10-15 2018-12-13 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ プロテアソーム阻害剤およびその用途
CN113105486A (zh) * 2021-02-24 2021-07-13 南京师范大学 一种硼酸酯类化合物及其药学上可接受的盐、其制备方法及其用途
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510245A (ja) * 1994-10-28 1998-10-06 プロスクリプト・インコーポレーテッド ボロン酸エステルおよびボロン酸化合物、合成および使用
JP2004517931A (ja) * 2001-01-25 2004-06-17 アメリカ合衆国 ボロン酸化合物製剤
WO2013033396A2 (fr) * 2011-08-30 2013-03-07 Trustees Of Tufts College Inhibiteurs de protéasome activés par fap utilisés pour traiter les tumeurs solides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510245A (ja) * 1994-10-28 1998-10-06 プロスクリプト・インコーポレーテッド ボロン酸エステルおよびボロン酸化合物、合成および使用
JP2004517931A (ja) * 2001-01-25 2004-06-17 アメリカ合衆国 ボロン酸化合物製剤
WO2013033396A2 (fr) * 2011-08-30 2013-03-07 Trustees Of Tufts College Inhibiteurs de protéasome activés par fap utilisés pour traiter les tumeurs solides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAMURA, S. ET AL.: "Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 2014, pages 2726 - 2735 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
JP2018536635A (ja) * 2015-10-15 2018-12-13 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ プロテアソーム阻害剤およびその用途
US11066397B2 (en) 2015-10-15 2021-07-20 Cornell University Proteasome inhibitors and uses thereof
US11629141B2 (en) 2015-10-15 2023-04-18 Cornell University Proteasome inhibitors and uses thereof
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11732005B2 (en) 2017-10-11 2023-08-22 Cornell University Peptidomimetic proteasome inhibitors
CN113105486A (zh) * 2021-02-24 2021-07-13 南京师范大学 一种硼酸酯类化合物及其药学上可接受的盐、其制备方法及其用途
CN113105486B (zh) * 2021-02-24 2023-08-15 南京师范大学 一种硼酸酯类化合物及其药学上可接受的盐、其制备方法及其用途

Also Published As

Publication number Publication date
JP6468562B2 (ja) 2019-02-13
JPWO2015076359A1 (ja) 2017-03-16

Similar Documents

Publication Publication Date Title
Hennessy et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)
JP6468562B2 (ja) プロテアソーム阻害性化合物
CN108164474B (zh) 作为免疫调节剂的1,2,4-二唑衍生物
JP6871310B2 (ja) ジペプチド及びトリペプチドエポキシケトンプロテアーゼ阻害剤
Ugwu et al. Synthesis, characterization, molecular docking and in vitro antimalarial properties of new carboxamides bearing sulphonamide
Alterman et al. Design and synthesis of new potent C 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold
Onaran et al. Squaric acid-based peptidic inhibitors of matrix metalloprotease-1
DE60209227T2 (de) 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
CA2777749C (fr) Peptides therapeutiques comportant un beta-amino acide disubstitue pour traiter les infections microbiennes ou les tumeurs
Cohen et al. Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold
Fehrentz et al. Solid phase synthesis of C-terminal peptide aldehydes
US20200253995A1 (en) Method to treat hypercholesterolemia by modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9) protein activity with small molecule ligands
Dai et al. Total synthesis of syringolin A
Lee et al. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants
JP4144811B2 (ja) ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター
Ozcan et al. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors
Küçükbay et al. Synthesis and carbonic anhydrase inhibitory properties of novel 4-(2-aminoethyl) benzenesulfonamide-dipeptide conjugates
Zask et al. Synthesis and Biological Activity of Analogues of the Antimicrotubule Agent N, β, β-Trimethyl-l-phenylalanyl-N-[(1 S, 2 E)-3-carboxy-1-isopropylbut-2-enyl]-N 1, 3-dimethyl-l-valinamide (HTI-286)
WO2017151587A1 (fr) Aldéhydes et cétones aza-peptidiques
Baranyai et al. In vitro biological evaluation of new antimycobacterial salicylanilide-tuftsin conjugates
Pacifico et al. Synthesis and biological activity of peptide α-ketoamide derivatives as proteasome inhibitors
CA2943817C (fr) Compose epoxycetone tripeptidique construit a partir d'un heterocycle et procede pour le preparer et l'utiliser
Graf von Roedern et al. Design and synthesis of malonic acid-based inhibitors of human neutrophil collagenase (MMP8)
Schade et al. Highly selective sub-nanomolar cathepsin S inhibitors by merging fragment binders with nitrile inhibitors
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14864020

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015549201

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14864020

Country of ref document: EP

Kind code of ref document: A1